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Abstract
Background: Human T-cell leukemia virus-associated adult T-cell leukemia-lymphoma (ATLL) has a very poor prognosis,
despite trials of a variety of different treatment regimens. Virus expression has been reported to be limited or absent when
ATLL is diagnosed, and this has suggested that secondary genetic or epigenetic changes are important in disease
pathogenesis.
Methods and Findings: We prospectively investigated combination chemotherapy followed by antiretroviral therapy for
this disorder. Nineteen patients were prospectively enrolled between 2002 and 2006 at five medical centers in a phase II
clinical trial of infusional chemotherapy with etoposide, doxorubicin, and vincristine, daily prednisone, and bolus
cyclophosphamide (EPOCH) given for two to six cycles until maximal clinical response, and followed by antiviral therapy
with daily zidovudine, lamivudine, and alpha interferon-2a for up to one year. Seven patients were on study for less than
one month due to progressive disease or chemotherapy toxicity. Eleven patients achieved an objective response with
median duration of response of thirteen months, and two complete remissions. During chemotherapy induction, viral RNA
expression increased (median 190-fold), and virus replication occurred, coincident with development of disease progression.
Conclusions:EPOCHchemotherapyfollowedbyantiretroviraltherapyisanactivetherapeuticregimenforadultT-cellleukemia-
lymphoma, but viral reactivation during induction chemotherapy may contribute to treatment failure. Alternative therapies are
sorely needed in this disease that simultaneously prevent virus expression, and are cytocidal for malignant cells.
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Introduction
Human T-cellleukemia virustype1 (HTLV-1) isa memberof the
deltaretrovirusfamily[1].Infectionsare prevalent insouthern Japan,
the Caribbean Islands, parts of Central and South America, the
MiddleEast, and Africa, where10–15%of the population is infected
[2]. In the United States, 0.025% of volunteer blood donors are
infected with HTLV-1, or the closely related retrovirus, HTLV-2.
Infections by either virus are common among intravenous drug
abusers.
HTLV-1 includes gag, pro, pol, and env genes, encoding the capsid
of the virion, the viral protease, the viral reverse transcriptase and
integrase enzymes, and the glycoprotein required for viral entry [1].
Several regulatory genes are critical for virus replication, spread, and
pathology, especially tax which is capable of immortalizing lymphoid
cells in culture and in mouse model systems. Tax-mediated
transcriptional activation of nuclear factor kB( N F kB)-target genes
is critical for resistance to apoptotic stimuli [2]. Tax also has an
important role in T cell activation, proliferation, and genetic
instability, factors critically important in leukogenesis [1].
Two to five percent of HTLV-1 infected patients develop
myelopathy or a lymphoid malignancy, designated adult T-cell
leukemia lymphoma (ATLL) [4,5]. ATLL is classified as
smoldering in about 5% of cases, chronic in 15% of cases, acute
or leukemic in 60% of cases, and lymphomatous ATLL in 20% of
cases [6]. Whereas smoldering and chronic ATLL are associated
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survival of patients with leukemic and lymphomatous forms of
ATLL is 0.5–2.0 yrs. ATLL is usually a malignancy of CD4+ T
regulatory cells, although suppressor activity may be lacking, and
occasional examples of CD8+ lymphoid malignancy have also
been described [7–10]. ATLL is classified in a separate category in
the Revised European American Lymphoma Classification, and as
a peripheral T cell lymphoma in the World Health Organization
classification [11,12]. ATLL is characterized by frequent blood
and bone marrow involvement, hypercalcemia, and lytic bone
lesions [4].
HTLV-1 is uniformly associated with ATLL, as determined by
antibody or nucleic acid assays, and clonality of HTLV-1 in tumor
cells [1]. Nevertheless, viral expression is limited or absent when
patients present with ATLL [1]. It has been hypothesized that
Tax, and perhaps other HTLV-1 genes, are critical for initiation of
the T-cell malignancy, but secondary genetic or epigenetic
changes are required for disease progression.
Treatment approaches, with variable levels of success for ATLL
have included various chemotherapy regimens, a combination of
zidovudine and interferon alpha-2a, antibody or antibody-radio-
conjugate therapy, stem cell transplantation, or targeted ap-
proaches with bortezomib or arsenic trioxide [4,5,13].
The objectives of the current trial were to assess the efficacy of
EPOCH chemotherapy followed by antiretroviral therapy in
patients with the acute forms of ATLL, and evaluate the effects of
therapy on HTLV-1 DNA and RNA load. The EPOCH regimen
was chosen based on demonstrated activity in uninfected
individuals with refractory B-cell non-Hodgkin’s lymphomas,
and in HIV-associated lymphomas [14,15]. The antiretroviral
therapy with interferon and zidovudine was selected based on
demonstrated activity in the leukemic variant of ATLL [16,17].
The addition of lamivudine to the antiretroviral therapy regimen
was based on reported activity in HTLV-1 associated myelopathy
[18]. Sequential, rather than concurrent therapy was chosen to
avoid synergistic toxicity of the chemo- and anti-viral therapies.
Methods
Patient Selection
Inclusion criteria for the study were histologically or cytolog-
ically documented ATLL, with CD3+ tumors, documented
HTLV-1 infection, evaluable or measurable disease, and adequate
hematologic (absolute neutrophil count; ANC.1000, platelet
count.75,000/mm
3), hepatic (biliruin,2.0, transaminases,7
times upper limit of normal), and renal function (creatinine,2.0)
unless abnormalities were due to ATLL involvement (Protocol S1).
The study included patients with a Karnofsky performance score
of at least 50%, at least 18 yrs of age who signed the informed
consent, and allowed patients with prior treatment for ATLL.
Exclusion criteria were active opportunistic infection requiring
therapy, concurrent malignancy other than in situ cervical cancer
or non-metastatic, non-melanomatous skin cancer, untreated
thyroid disease, autoimmune disease, uncontrolled psychiatric
disease, pregnancy or breastfeeding. Patients at any one of 50
different sites in the United States were eligibile for participation.
Institutional review board approval was obtained at all enrolling
sites, which included Memorial Sloan Kettering Cancer Center,
New York, NY; Albert Einstein College of Medicine, University of
Miami School of Medicine, Johns Hopkins University Medical
Institutions, and Massachusetts General Hospital, as well as the
coordinating site, Washington University School of Medicine.
Written informed consent was obtained from all participants in the
study.
Treatment
EPOCH therapy was administered as follows: etoposide 50 mg/
m
2/d, vincristine 0.4 mg/m
2/d, and doxorubicin 10 mg/m
2/d
each given as a continuous 96 hr infusion on days 1–4,
cyclophosphamide 750 mg/m
2 given IV on day 5, and prednisone
60 mg/m
2 given orally on days 1–5. Chemotherapy was
administered on a 21–28 days cycle for a minimum of 2 cycles
beyond best response and a maximum of six cycles (Fig 1). In
contrast to the intra-patient dose modification in the NIH
EPOCH regimen, no dose adjustments were planned based on
the previous cycle’s nadir blood counts. Responses were evaluated
by standard criteria using clinical tumor measurements, peripheral
blood absolute lymphocyte measurements, bone marrow biopsies,
and CT scans [19]. ‘‘Best response’’ was defined as the response
achieved when one or more additional cycles of chemotherapy
were given and no additional tumor shrinkage was noted. For
patients with stable disease or progressive disease, no additional
chemotherapy was given. For patients with partial or complete
remission, two additional cycles of chemotherapy were given, but
no more than six cycles of chemotherapy. G-CSF was given at a
dose of 5 ug/kg/d subcutaneously daily beginning 24 hrs after the
administration of prednisone for 10 days beginning on day 6 or
until ANC recovered to at least 4000 cells/mm
3. Prophylaxis for
Pneumocystis pneumonia was provided with co-trimoxazole,
dapsone, or inhaled pentamidine. Allopurinol was recommended
for seven days during the first cycle for patients with absolute
lymphocyte count.50,000 or LDH.500 U/dl. Central nervous
system prophylaxis was at the discretion of the investigator with
either 50 mg cytosine arabinoside or 12 mg of intrathecal
methotrexate administered on days 1, 8, 15, and 22 of the first
chemotherapy cycle. One month after the last cycle of chemo-
therapy, antiretroviral therapy was initiated, which included
zidovudine 300 mg bid plus lamivudine 150 mg bid (separately
or as CombivirH) and interferon alpha-2a 9 mU subcutaneously
per day for 1 yr.
Baseline evaluations included HTLV-1 serology, confirmatory
immunoblot or PCR, hematology, blood chemistries, T-cell
subsets, serum pregnancy test if appropriate, CT or MRI scans
of the chest abdomen, and pelvis, bone marrow aspirate and
biopsy, and lumbar puncture, HTLV-1 viral DNA and RNA.
Evaluations during chemotherapy included blood chemistries and
hematology with each cycle, and restaging CT and HTLV-1 viral
DNA and RNA at the beginning of each odd numbered cycle and
every 3 mos of antiretroviral therapy. Bone marrow biopsy was
repeated at the beginning of each odd numbered cycle if positive
at initiation of therapy.
Chemotherapy was delayed one week if ANC,1000 or
platelets,75,000, and reduced if still depressed at that time.
Reductions in doxorubicin and vincristine doses were prescribed if
bilirubin was elevated. Doxorubicin was discontinued for conges-
tive heart failure, and vincristine was discontinued for grade 3 or
greater neurotoxicity. Interferon was discontinued and restarted at
5 mU/d if there was grade 3 fever, fatigue, anorexia, or mood
disturbance. Interferon, zidovudine, and lamivudine were discon-
tinued and restarted at a lower dose of interferon but full dose of
combivir after recovering from grade 3 anemia, neutropenia,
thrombocytopenia, or transaminase elevation. For recurrence of
these toxicities, or persistent toxicities for more than thirty days, or
other grade 4 toxicities, antiviral medications were permanently
discontinued.
Endpoints and Statistics
Patients were withdrawn from study if they developed a life
threatening infection, chemotherapy was delayed for more than six
ATLL Chemo-Antiviral Therapy
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after two cycles of chemotherapy.
The target sample size was 29 subjects, but the study was closed
after enrollment of 19 subjects due to slow accrual. The target
sample size was based on a two-stage test of the null hypothesis
that the overall response rate was ,10%, against the alternative
hypothesis that it was .30%, at the one-sided significance level of
5% and a power of 80% [20]. There were 10 patients in the first
stage, and at least two objective responses were required to
proceed with enrollment.
Binomial proportions and 95% confidence intervals were used
to estimate response rates to therapy. Logistic regression analyses
were used to evaluate baseline characteristics and other covariates
with response. The Kaplan-Meier method was used to evaluate
the response duration and overall survival. Analysis of variance
was used to evaluate the effects of treatment and time on the viral
DNA load measurements, and measurements of viral transcripts.
A paired two-tailed t test was used to assess viral RNA and DNA
values after logarithmic conversion at initiation of treatment
compared to time when polymerase changes were noted.
Viral DNA and RNA Measurements and Sequence
Analyses
The HTLV-1 DNA assay, performed with peripheral blood
mononuclear cells (PBMCs), prepared in a BSL3 facility,
measured the number of copies of integrated or unintegrated
viral genome using ABI PRISM 7700 sequence detector (Perkin
Elmer/Applied Biosystems) with primers in pX [21]. The assay
was standardized by measuring the number of copies of b-actin
DNA, and performed in triplicate. The amount of HTLV-1
proviral DNA was calculated as copy number of HTLV-1 per 100
PBMC=[(copy number of px)/(copy number of b-actin/2)]6100.
The HTLV-1 RNA assay was performed with PBMCs. RNA
extraction, complementary DNA (cDNA) synthesis, and real time
PCR were performed with primers designed for amplification of
HTLV-1 tax cDNA, and human housekeeping gene hypoxanthine
ribosyl transferase (hprt) for internal calibration [22]. Standard
curves were generated using cDNA from MT-2 cells, and all assays
done in duplicate, with correlation values of standards more than
99%. The relative tax mRNA load was calculated by the following
formula: HTLV-1 tax mRNA load={(value of tax)/(value of
hprt)}610,000.
For DNA sequence analysis, genomic DNA was isolated from
PBMCs using the Qiagen QIAamp DNA blood kit. PCR was
carried out to amplify the pol gene (nt 2625–3195) encoding aa. 41-
219, followed by automated DNA sequencing with Big Dye
terminator V3.1.
Results
Patient Characteristics
Nineteen patients with CD4+ HTLV-1+ acute or lymphoma
ATLL were enrolled between October, 2002 and February, 2006
at 5 medical centers in the United States (see Checklist S1).
Characteristics of the patients at baseline and during their course
of therapy are shown in Table 1. At baseline, an elevated absolute
lymphocyte count was seen in 6 patients (range 400–127,000/cu
mm), hypercalcemia in 1 patient, and stage III–IV disease in 16 of
18 patients; in one patient, staging was not completed for medical
reasons. The LDH was elevated in 15 patients, performance status
was 2–4 for 9 patients, age .60 yrs for 6 of 19 patients, and
involvement of 2 or more extranodal sites in 5 of 18 patients. The
revised International Prognostic Index score was 1–2 in 7 patients,
and 3–5 in 11 patients [23].
Figure 1. Treatment Schema. Subjects were treated with EPOCH chemotherapy for cycles 1 and 2 and then responses assessed. Patients with
complete remissions (CR) or partial remissions (PR), received cycles 3 and 4, whereas patients with stable disease received antiviral therapy. Similar
treatment assignments were applicable after cycles 3 and 4, with patients in CR or PR receiving cycles 5 and 6 EPOCH therapy, except for one patient
who was in CR after cycles and 1 and 2, and remained in CR after cycles 3 and 4, and one patient in PR after cycles 1 and 2 and achieved ‘‘best
response’’, i.e. PR after cycles 3 and 4, who then received antiviral therapy. Subjects with stable disease, PR, or CR after 6 cycles of therapy then
received antiviral therapy. Subjects with disease progression or toxicity during any stage of treatment, were taken off the treatment protocol, and
were eligible to receive non-protocol therapies.
doi:10.1371/journal.pone.0004420.g001
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4 day continuous infusion of etoposide, vincristine, and doxoru-
bicin, day 5 cyclophosphamide, 5 days of prednisone, followed by
10 days of G-CSF. Five patients received 1 cycle of chemotherapy,
7 patients received 2–4 cycles of chemotherapy, and 7 patients
received 5–6 cycles of chemotherapy (Fig 1). After completion of
chemotherapy, 6 patients who had not manifested ATLL
progression received antiviral therapy for a median of 1.5 mos
(average of 3.4 mos, range 1–9 months); 2 eligible patients
declined antiviral therapy.
Seven patients were non-evaluable, since they were on study for
less than one month. This includes three patients with progressive
disease, one patient each who died during the first cycle with
fungal sepsis, cardiotoxicity, respiratory failure, or tumor lysis
syndrome (Table 1).
Viral RNA Expression
Levels of viral RNA and DNA were determined in PBMCs in
43 samples from these subjects, by real time PCR and RT-PCR
assays (Supplementary Table S1). Viral DNA measurements were
not predictive of response (not shown)
Viral RNA levels were normalized for levels of hprt mRNA
(Supplementary Table S1). At diagnosis, viral RNA was
undetectable in 6 subjects, expressed at 1.6-24 copies per 10
4
copies of hprt RNA in 6 subjects, and at 180-283,000 copies per
10
4 copies of hprt RNA in 3 subjects. Multiple samples were
available for viral RNA measurements in 12 patients during their
treatment course (Supplementary Table S1). In three subjects, no
changes in viral RNA were detected (subjects 3, 10, 11). In two
subjects, variable levels of viral RNA were seen during the course
of treatment, variably low levels in subject 19 (0.6-55 copies per
10
4 copies of hprt RNA), and variably high levels in subject 17
(2250-14,000 copies per 10
4 copies of hprt RNA). In 6 subjects
increasing viral RNA levels were found during the course of
therapy (median 190-fold increase, range 11.8-97,800 fold
increase; subjects 8, 9, 12, 13, 14, 15). In subject 16, decreasing
viral RNA levels were seen over the course of therapy.
The portion of the pol gene encoding residues 41-219 of reverse
transcriptase was sequenced from PBMCs obtained at the same
time points used for viral RNA measurements. Changes in coding
sequences were found at 0-5 residues over the course of therapy in
different patients (Supplementary Table S1). Changes in pol were
found in 4 of 6 patients with increasing viral RNA levels (subjects
8, 9, 12, and 15) and 2 of 4 patients that did not manifest
increasing viral RNA levels (subjects 10 and 16 versus subjects 3
and 11). In the subjects with changes in pol and increasing viral
RNA levels, these changes occurred at the same time (Fig 2 and
Supplementary Table S1). Overall, eight of twelve patients had
changes in pol sequence and/or increases in viral RNA expression,
during the course of therapy, and a ninth patient had variable high
levels of viral RNA throughout the treatment course.
Responses
Eleven of twelve evaluable patients (or 11 of 19 total patients)
had responsive disease, including two complete remissions and
nine partial remissions, for an overall response rate of 91% for
evaluable patients and 58% for all patients (95% confidence
intervals from 60% to 99% and 36% to 77%, respectively). Disease
relapsed in four patients after 1, 1, 13, and 18 mos, respectively.
Progression-free and overall survival curves are shown in Fig 3.
Nine patients are alive at the time of this report, at 0, 1, 3, 4, 5, 7,
11, and 16 mos after completion of therapy.
Table 1. Patient Characteristics
Subject # ALC Stage PS2-4 LDH elevation Age.60 .2 extranodal IPI Best Response
1 2400 IV yes yes yes no 4 NE-sepsis
2 1400 III yes yes no yes 4 NE-toxicity
3 17200 IV yes yes no yes 4 NE-toxicity
4 1900 IV yes yes no no 3 NE-toxicity
5 1600 II no yes yes no 2 NE-PD
6 127000 IV no yes no yes 3 NE-PD
7 11700 ND yes no yes no ND NE-PD
8 2000 IV no no no no 1 PD
9 66000 IV yes yes no no 3 PR
10 17000 III no no no no 1 PR
11 500 IV no no no yes 2 PR
12 400 I no yes no no 2 PR
13 5400 IV no yes yes no 3 PR
14 500 IV yes yes yes no 4 PR
15 2300 IV no yes no no 2 PR
16 1800 III no yes no no 2 PR
17 1100 IV yes yes no yes 4 PR
18 1400 IV no yes yes no 3 CR
19 1500 IV yes yes no no 3 CR
Key: ALC, absolute lymphocyte count; PS, performance status (ECOG);
LDH, lactate dehydrogenase; IPI, international prognostic index; ND, not done;
CR, complete remission; NE, not evaluable; PR, partial remission; PD, progressive disease
doi:10.1371/journal.pone.0004420.t001
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The response rates, duration of responses, and overall survival
of the current trial are similar to previous trials of ATLL. The
most recent published Japanese cooperative ATLL trial utilized
the LSG15 protocol, and included 58 patients with leukemic
ATLL, 28 patients with lymphoma type, and 10 patients with
unfavorable chronic ATLL [24]. Patients received seven cycles of
VCAP (vincristine, cyclophosphamide, doxorubicin, and predni-
sone), AMP (doxorubicin, ranimustine, and prednisone), and
VECP (vindesine, etoposide, carboplatin, and prednisone). This
resulted in 35% complete remissions and 45% partial remissions,
median survival of 13 mos, and 31% 2-yr survival.
The limitations of the current trial include the small number of
patients, and several patients were non-evaluable. The high
proportion of non-evaluable patients is likely due to the intensity of
the treatment regimen and the poor prognostic features of the
enrolled patients. In addition, only six patients received antivirals,
and no patient received the planned 12 mos of antiviral therapy,
making it impossible to evaluate the relative contribution of this
therapy in the trial.
Viral DNA measurements were feasible, but did not have
prognostic or predictive power. However, results of viral RNA
measurements were quite unexpected. Although much of the
literature suggests that little if any viral RNA is expressed in
patients at the time of presentation with ATLL [25–28], in fact,
the majority of our patients had detectable tax viral RNA at
diagnosis, including 3 of 15 patients with high levels of viral RNA
at presentation. During the course of therapy, viral RNA levels
were measured on subsequent samples in 12 subjects. In 6 of these
subjects, increased viral RNA levels were found on subsequent
measurements, and in one other patient with a high initial viral
level, variably high levels were found at subsequent measurements.
In 4 of 6 patients with increasing viral RNA levels during the
course of therapy, changes were first identified in the reverse
transcriptase open reading frame at the same time. Sequence
changes in reverse transcriptase did not correspond with those
predicted to give rise to zidovudine or lamivudine-resistance based
on studies of HIV-1 reverse transcriptase, and generally preceeded
antiviral therapy [29]. These sequence changes may have arisen
from selection of rare viral variants, or more likely, as a result of
error-prone retrovirus replication. Such sequence changes have
not been described in patients who are not undergoing therapy
[30–32].
The finding of virus expression and mutation raises questions as
to whether or not these activities are related to ATLL relapse or
progression. If there is such a relationship, virus expression and
mutation could be a marker of progression, perhaps a manifes-
tation of lymphocyte activation [33]. Alternatively, virus expres-
sion and mutation could be a cause of progression, possibly
through generation of clonal heterogeneity of infected tumor cells.
This could result from changes in the viral integration site which
Figure 2. Viral RNA Changes with Polymerase Changes. The
figure shows initial viral RNA and DNA values for subjects (8, 9, 12, and
15) and subsequent values for each subject on the same line (at
respective times 166, 191, 284 and 47 d from treatment initiation),
obtained at the time that a change in the polymerase coding capacity
was detected (see Supplementary Table S1). For two additional subjects
(13 and 14), viral RNA values are available at the initial and subsequent
time points, but no changes in polymerase coding capacity were
detected. The logarithmic mean, 95% confidence intervals, and results
of a two-tailed paired sample t test are presented for comparisons of
the values at these time points. All of the viral RNA and DNA values and
polymerase changes are provided in Supplementary Table S1.
doi:10.1371/journal.pone.0004420.g002
Figure 3. Duration of response and disease-free survival of all
patients on the study.
doi:10.1371/journal.pone.0004420.g003
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sequences, or for integration in sites that are more transcriptionally
active [25]. Alternatively, this could be due to therapy-mediated
clearance of clonal ATLL cells carrying quiescent virus, and
subsequent repopulation and infection of T cells with HTLV-1.
Changes in integration sites during the treatment course were
confirmed in several of these patients (not shown). Another
possibility is that virus expression or mutation results in secondary
genetic events that select for tumor progression, independent of
new integration events [34]. In either event, incorporation of
antiviral therapy earlier in the course of therapy could be
beneficial.
Although most evaluable patients achieved responses, responses
were not long, with relapses occurring during or shortly after
completion of chemotherapy in many patients. Thus, more
effective therapies are required. Although the leukemic form of
ATLL responds well to zidovudine and alpha interferon-2a, the
lymphomatous form is poorly responsive to most therapies [16,17].
Various strategies might be considered to improve current
chemotherapy regimens, such as simultaneous use of chemother-
apy and antiviral agents, addition of a proteasome inhibitor or
other agent to overcome NFkB-induced chemotherapy resistance
[35,36], or p53 inactivation in tumor cells [37]. Alternatively,
chemotherapy combined with antibody or antibody conjugates
may be considered [38]. Approaches using allogeneic stem cell
transplantation, perhaps earlier in the course of disease, may be
appropriate for younger patients for whom a donor can be
identified [39]. The current trial of chemoantiviral therapy and the
translational studies of viral RNA provide novel insights to
improve therapy for this hematopoietic malignancy.
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